INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

About this update from Inmune Bio Inc.

[{"type":"image","alt":"INmune Bio, Inc.","displaySize":"","headline":null,"caption":"INmune Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ESFQnG17m_59Q1hSBmvAug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60}},"lazy":false},{"type":"text","content":"Company to Host Conference Call Today, March 27, at 4:30pm ET","length":61,"tagName":"p"},{"type":"text","content":"BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update.","length":364,"tagName":"p"},{"type":"text","content":"Full Year 2024 and Recent Corporate Highlights  ","length":56,"tagName":"p"},{"type":"text","content":"DN-TNF Platform Highlights (XPro1595, XPro™):","length":45,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced completion of enrollment for its Phase 2 trial on Friday, 27 September, 2024. This global, blinded, randomized Phase 2 trial (the “AD02 trial”) is focused on patients with Early Alzheimer’s Disease (AD) and biomarkers of elevated neuroinflammation. Final enrollment of 208 patients exceeded the trial’s target enrollment of 201 patients.","length":347,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed two separate interim analyses of blinded data from its AD02 trial. The analyses demonstrated exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between baseline EMACC and Clinical Dementia Rating-Sum of Boxes (CDR-SB). Key findings of the analysis included:","length":320,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Statistical Correlation: An independent review confirmed a significant correlation (p<0.001) between baseline scores on EMACC and CDR-SB, the key cognitive endpoints in the AD02 trial.","length":187,"tagName":"p"}]},{"val":[{"type":"te...

More updates from Inmune Bio Inc.